The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas.
The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy, according to a May 4 Guardant Health news release.
The approval enables a noninvasive approach to guide treatment selection, as ESR1 mutations are linked to resistance to endocrine therapy. The therapy, developed by Arvinas and Pfizer, is designed to degrade the estrogen receptor and target tumors driven by ESR1 mutations, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
